MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

General Information

Summary To determine the maximum tolerated dose (MTD) of FT538 monotherapy when administered via intraperitoneal (IP) catheter and in combination with intravenous (IV) enoblituzumab in patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer.
Clinical trials phase Phase 1
Start date (estimated) 2023-04-28
End date (estimated) 2028-09-30
Clinical feature
Label ovarian cancer
Description A female reproductive organ cancer that is located_in the ovary.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT05708924
ICTRP weblink
Other study identifiers
Name 2021LS103
Source weblink
Public contact
Public email
First name Melissa
Last name Geller
Phone +1 612 676-4200
United States
Address freetext Masonic Cancer Center - University of Minnesota Recruiting Minneapolis, Minnesota, United States, 55455
Sponsors Masonic Cancer Center, University of Minnesota


Which differentiated cell type is used
Label natural killer cell
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Suspended
Comment recruitment status Product withdrawn from clinical development
Estimated number of participants 33